methylprednisolone sodium succinate

Prompt multidisciplinary management with high-dose intravenous methylprednisolone, plasmapheresis, and intravenous immunoglobulin led to a gradual and significant improvement in cognitive function and GCS, with no recurrence of encephalitis during follow-up. This case highlights the critical importance of maintaining a high index of suspicion for atezolizumab-induced CNS encephalitis, emphasizing the need for early diagnosis, comprehensive diagnostic evaluation, and aggressive immunosuppressive therapy to achieve favorable neurological outcomes in patients receiving immune checkpoint inhibitors.

P2, N=60, Enrolling by invitation, Cedars-Sinai Medical Center | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026

P2, N=50, Recruiting, Nanjing University School of Medicine

P=N/A, N=30, Recruiting, Assiut University | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

Management involved permanent discontinuation of cetuximab, high-dose intravenous methylprednisolone (1.5 mg∙kg-1∙day-1), cyclosporine (3 mg∙kg-1∙day-1), supportive wound care in a burn unit, and topical ocular/oral care...Therapy was successfully transitioned to bevacizumab plus FOLFOX after dermatologic recovery, with no rash recurrence during follow-up. This case highlights the importance of early recognition, multidisciplinary management, and protocol-driven intervention for severe cetuximab-induced skin toxicity to ensure patient safety and treatment continuity.

Treatment with intravenous methylprednisolone pulse therapy with plasma exchange resulted in marked clinical recovery and SEP normalization, with only mild residual paresthesia at two-year follow-up...In post-COVID-19 MRI-negative myelitis, SEPs offer critical diagnostic and prognostic information. Early recognition and timely escalation of combination immunotherapy may optimize neurological outcomes.

P=N/A, N=104, Completed, Nida Koçer Nazlıgül

Therapeutically, acute management relies on high-dose intravenous methylprednisolone (IVMP), with plasma exchange for steroid-refractory cases; long-term maintenance is subtype-tailored. Prognosis varies by subtype, with MOG-ON showing better recovery than AQP4-ON, and CRMP5-IgG-associated ON carrying poor outcomes. Even with breakthroughs in pathogenetic understanding and targeted treatments, challenges reinforce the importance of continued interdisciplinary research to optimize AON management.

Initial therapy comprised high-dose methylprednisolone, intravenous immunoglobulin and thalidomide, followed by surgical resection and adjuvant thalidomide-cyclophosphamide-prednisone. Postoperatively, inflammatory indices normalized and mucocutaneous lesions partially improved; nevertheless, the patient died of respiratory failure 6 months after surgery. In summary, the present case report aimed to provide valuable references and experiences for clinicians in the diagnosis and treatment of CD featuring PNP and FDCS.

The patient was admitted and commenced on intravenous methylprednisolone, leading to symptom resolution within 7 days. Understanding the pathophysiological mechanisms underlying these toxicities is essential for optimizing treatment strategies, minimizing adverse effects without compromising ICI efficacy, and ultimately prolonging patient access to immunotherapy. Further research into immune-related dermatological conditions may also provide valuable insights into the molecular mechanisms governing endogenous dermatological diseases, offering new avenues for targeted dermatological therapies.

P=N/A, N=20, Recruiting, University of Chicago | Trial primary completion date: Sep 2025 --> Jun 2030

P2, N=60, Recruiting, Cynata Therapeutics Limited | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Mar 2026